Altracel licenses wound care tech to HemCon
Dublin, Ireland-based Altracel Pharmaceuticals, a specialist health care innovation group, says that its Czech subsidiary Nanopeutics has licensed its chitosan-based Nanospider wound care technology to US military hemorrage control specialist HemCon Medical Technologies. The deal, financial terms of which were not provided, follows the successful completion of product testing in both the USA and Czech Republic earlier this year.
Additionally, Altracel announced that it has created a new health care services division, designed to provide it with increased research, clinical trial and developmental capabilities. The new unit will also offer these services to external organizations, and is expected to begin generating revenue by the end of the year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze